RIGEL PHARMACEUTICALS INC (RIGL) research
RIGEL PHARMACEUTICALS INC- Sector
- Biotechnology
- Last price
- $47.15
- As of
RIGEL PHARMACEUTICALS INC (RIGL): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-04.
As of . Source: SEC EDGAR filings for RIGL. Method and limitations.
Share the RIGL intelligence card
See the full RIGL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RIGL on one page. Preview it with sample data, then open it live with a free account.
Preview the RIGL dossierActive signals for RIGL
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 39.2%, EPS $0.88 vs $0.6324 estimate
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 65% of RIGL (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 57% of RIGL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +69% to RIGL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +144% to RIGL (2026Q2)
FREE, NO ACCOUNT
Every signal on RIGL, as it fires
You are seeing 5 of 10 signals recorded on RIGL since 2026-05-26.
The five above landed across 2 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RIGL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 766559702 · 2026Q2 | $21.2M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 766559702 · 2026Q2 | $8.1M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 766559702 · 2026Q2 | $5.7M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 766559702 · 2026Q2 | $3.7M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RIGL
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
RIGL against its peers
RIGL's operating margin of 42.6% ranks in the 95th percentile of 9 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | RIGL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 294M USD | 58.6M USD | 86 | 10 |
| Operating margin | 42.6% | -187.2% | 95 | 9 |
| Net margin | 124.7% | -164.4% | 95 | 9 |
| Return on equity | 93.8% | -38.3% | 97 | 17 |
| P / E | 2.4x | n/a | n/a | 1 |
Peers (18): JBIO, TBPH, ARDX, SANA, SGP, CGEM, LXRX, KURA, ABUS, CRVS, AVTX, GERN, ACHV, MLTX, GLUE, JANX, DSGN, FDMT. Left out: APMD (no annual filing), IVA (period gap), HELP (period gap), OBX (no annual filing), ATTO (no annual filing), ANL (period gap), ODTX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (RIGL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more RIGL signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to RIGLand get the insider, 13F, options, and confluence read in one view.